2022
DOI: 10.1111/joim.13600
|View full text |Cite
|
Sign up to set email alerts
|

Optimizing the vaginal microbiome as a potential strategy to reduce heterosexual HIV transmission

Abstract: Bacterial vaginosis (BV) is a proinflammatory genital condition characterized by high vaginal bacterial diversity and a paucity of Lactobacillus species. BV has been linked to an elevated risk of HIV acquisition among HIV‐negative women and of forward HIV transmission to male sex partners among women living with HIV (adjusted hazard ratios of 1.69 and 3.17, respectively), potentially by eliciting genital inflammation in women with BV and their male sex partners. BV is also highly prevalent among women in sub‐S… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
2
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(7 citation statements)
references
References 95 publications
0
2
0
1
Order By: Relevance
“…Linking microbiome findings to changes in the tumor microenvironment may be further explored, as recently reported for VSCC ( Rustetska et al, 2023 ). Novel treatments could be developed based on microbial targets, as previously attempted for bacterial vaginosis and genitourinary symptoms ( Falagas et al, 2007 ; Armstrong et al, 2022 ; Yoshikata et al, 2022 ). Studies to new treatment modalities, such as the current clinical trial applying the topical JAK-inhibitor ruxolitinib in LS, could consider assessing the microbiome composition as exploratory biomarker ( Rissmann et al, 2020 ; Papp et al, 2022 ; ClinicalTrials.gov, 2023e ).…”
Section: Discussionmentioning
confidence: 99%
“…Linking microbiome findings to changes in the tumor microenvironment may be further explored, as recently reported for VSCC ( Rustetska et al, 2023 ). Novel treatments could be developed based on microbial targets, as previously attempted for bacterial vaginosis and genitourinary symptoms ( Falagas et al, 2007 ; Armstrong et al, 2022 ; Yoshikata et al, 2022 ). Studies to new treatment modalities, such as the current clinical trial applying the topical JAK-inhibitor ruxolitinib in LS, could consider assessing the microbiome composition as exploratory biomarker ( Rissmann et al, 2020 ; Papp et al, 2022 ; ClinicalTrials.gov, 2023e ).…”
Section: Discussionmentioning
confidence: 99%
“…На сьогодні взаємодії між мікроорганізмами піхви та хазяїном залишається предметом інтенсивних постійних досліджень, оскільки зміщення мікробіоти піхви від Lactobacillus до більш різноманітних видів бактерій, включаючи факультативні анаероби, призводить до розвитку бактеріального вагінозу. Наслідками останнього є, насамперед, підвищена сприйнятливість до урогенітальних інфекцій [2][3][4][5], включаючи вірус імунодефіциту людини (ВІЛ) [6], та передчасні пологи [7,8].…”
Section: Modern Approaches To Restoring Vaginal Microbiocenosis O a T...unclassified
“…On the opposite, the higher HIV risk is associated with CST IV (the diversity group, encompassing bacterial vaginosis and aerobic vaginitis/desquamative inflammatory vaginitis). The role of CST III (L. iners) is more controversial but seems to be a less favorable profile [18][19][20]. The protective effect against HIV is partially mediated by extracellular vesicles released by the symbiotic bacteria [21].…”
Section: The Female Genitourinary Tract In Wlhivmentioning
confidence: 99%